Abstracts
Résumé
La myopathie de Duchenne est due à l’absence d’une protéine du cytosquelette des fibres musculaires, la dystrophine. Celle-ci joue un rôle essentiel dans l’intégrité des complexes protéiques membranaires qui assurent la liaison avec la matrice extracellulaire. L’utrophine, codée au niveau du chromosome 6, présente 80 % d’homologie avec la dystrophine et est exprimée à la jonction neuromusculaire. L’utrophine peut-elle remplacer la dystrophine et corriger les anomalies structurelles et fonctionnelles de la myopathie ? Chez des souris transgéniques déficientes en dystrophine et surexprimant de grandes quantités d’utrophine, celle-ci occupe les structures fixant la dystrophine et la récupération des atteintes fonctionnelles, surtout mécaniques, peut être complète. Pour transformer cette approche expérimentale en traitement de la myopathie, les nombreuses recherches en cours visent à obtenir une surexpression d’utrophine dès l’apparition des symptômes myopathiques.
Summary
Duchenne muscle dystrophy results from the absence of dystrophin, a cytoskeletal protein of the muscle fibre. Dystrophin plays an essential role in the integrity of the membrane-associated protein complexes connected to the extracellular matrix. On chromosome 6 is located the gene of a protein presenting 80 % homology with dystrophin : utrophin, which is expressed at the neuromuscular junction. The review examines if utrophin can replace dystrophin and correct the structural and functional characteristics of the myopathy, and how the improvements can be quantitatively expressed. In transgenic mice, deficient in dystrophin, but overexpressing large quantities of utrophin, the latter is found on structures where dystrophin is normally located, histological signs of necrosis disappear and the recovery of functional disorders, specially affecting the mechanical properties of the muscle fibres, can be complete. The review examines also several ways of obtaining overexpression of utrophin in adult mdx mice, such as conditioned expression of the utrophin transgene (using a tetracycline-sensitive transactivator), transfection with viral vectors containing the utrophin cDNA (complete or truncated), actions on factor(s) controlling utrophin expression at the neuromuscular junction (heregulin, 4 N-acetylgalactosamine), and pharmacological ways of inducing expression (NO, arginine). Though partial improvements of the myopathy status have been obtained by these various approaches, they remain limited by their localized action and/or by the moderate level of utrophin expression obtained. Further researchs to overcome these limitations are urgently needed in order to transform the very promising effect of utrophin overexpression into a real treatment of Duchenne myopathy.
Appendices
Références
- 1. Matsumura K, Campbell KP. Dystrophin-glycoprotein complex : its role in the molecular pathogenesis of muscular dystrophies. Muscle Nerve 1994 ; 17 : 2-15.
- 2. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002 ; 82 : 291-329.
- 3. Engel AG, Yamamoto M, Fishbeck KH. Dystrophinopathies. In : Engel AG, Franzini-Armstrong C, eds. Myology : basic and clinical. New York : McGraw-Hill, 1994 : 1133-97.
- 4. Gillis JM. Understanding dystrophinopathies : an inventory of the structural and functional consequences of the absence of dystrophin in muscles of the mdx mouse. J Muscle Res Cell Motil 1999 ; 20 : 605-25.
- 5. Turner PR, Westwood T, Regen CM, Steinhardt RA. Increased protein degradation results from elevated free calcium levels found in muscle from mdx mice. Nature 1988 ; 355 : 735-8.
- 6. Loufrani L, Matrougui K, Gorny D, et al. Flow (shear stress)-induced endothelium-dependent dilation is altered in mice lacking the gene encoding for dystrophin. Circulation 2001 ; 103 : 864-70.
- 7. Rouger K, Le Cunff M, Steenman M, et al. Global/temporal gene expression in diaphragm and hindlimb muscles of dystrophin-deficient (mdx) mice. Am J Physiol Cell Physiol 2002 ; 283 : C773-84.
- 8. Bakay M, Zhao P, Chen J, Hoffman EP. A web-accessible complete transcriptome of normal human and DMD muscle. Neuromusc Disord 2002 ; 12 (suppl 1) : S125-41.
- 9. Boer JM, de Meijer EJ, Mank EM, et al. Expression profiling in stably regenerating skeletal muscle of dystrophin-deficient mdx mice. Neuromusc Disord 2002 ; 12 (suppl 1) : S118-24.
- 10. Tinsley JM, Blake DJ, Roche A, et al. Primary structure of dystrophin-related protein. Nature 1992 ; 360 : 591-2.
- 11. Fardeau M, Tomé FMS, Collin H, et al. Présence d’une protéine de type dystrophine au niveau de la jonction neuromusculaire dans la dystrophie musculaire de Duchenne et la souris mutante mdx. CR Acad Sci Paris Ser III 1990 ; 311 : 197-204.
- 12. Mizumo Y, Nonaka I, Hirai S, Ozawa E. Reciprocal expression of dystrophin and utrophin in muscles of Duchenne muscular dystrophy patients, female DMD carriers and control subjects. J Neurol Sci 1993 ; 119 : 43-52.
- 13. Deconinck AE, Rafael JA, Skinner JA, et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 1997 ; 90 : 717-27.
- 14. Deconinck N, Rafael JA, Beckers-Bleukx G, et al. Consequences of the combined deficiency in dystrophin and utrophin on the mechanical properties and myosin composition of limb and respiratory muscles of the mouse. Neuromusc Disord 1998 ; 8 : 362-70.
- 15. Tinsley JM, Potter AC, Phelps SR, et al. Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 1996 ; 384 : 349-53.
- 16. Deconinck N, Tinsley J, De Backer F, et al. Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice. Nat Med 1997 ; 3 : 1216-21.
- 17. Goudemant JF, Deconinck N, Tinsley JM, et al. Expression of truncated utrophin improves pH recovery in exercising muscles of dystrophic mdx mice. A 31P NMR study. Neuromusc Disord 1998 ; 8 : 371-9.
- 18. Tinsley J, Deconinck N, Fisher R, et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med 1998 ; 4 : 1441-4.
- 19. Xia B, Hoyte K, Kammesheidt A, et al. Overexpression of the CT GalNAc transferase in skeletal muscle alters myofiber growth, neuromuscular structure, and laminin expression. Dev Biol 2002 ; 242 : 58-73.
- 20. Nguyen HH, Jayasinha V, Xia B, et al. Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice. Proc Natl Acad Sci USA 2002 ; 99 : 5616-21.
- 21. Gilbert R, Nalbantoglu J, Petrof BJ, et al. Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles. Hum Gene Ther 1999 ; 10 : 1299-310.
- 22. Krag TOB, Juel-Jansen C, Hansen-Scwartz J, et al. Heregulin-mediated utrophin upregulation in mdx mice. J Neurol Sci 2002 ; 199 (suppl 1) : S89.
- 23. Chaubourt E, Fossier P, Baux G, et al. Nitric oxide and l-arginine cause an accumulation of utrophin at the sarcolemma : a possible compensation for dystrophin loss in Duchenne muscular dystrophy. Neurobiol Dis 1999 ; 6 : 499-507.
- 24. Delaporte S, Voisin V, Sébrié C, et al. The increase of utrophin in muscle of mdx mice treated by L-arginine reverses dystrophic phenotype and improves mechanical performance. J Neurol Sci 2002 ; 199 (suppl 1) : S88.
- 25. Squire S, Raymackers JM, Vandebrouck C, et al. Prevention of pathology in mdx mice by expression of utrophin : Analysis using an inducible transgenic expression system. Hum Mol Genet 2002 ; 11 : 3333-44.